The U.S. Food and Drug Administration (FDA) recently approved Tyruko (natalizumab-sztn, made by Sandoz, a division of the Novartis group). Tyruko is the first biosimilar disease-modifying therapy (DMT) for individuals…
Read More
Join RMMSC Medical Director Dr. Timothy Vollmer for an in-depth look at disease modifying therapies (DMTs) – the front line in our fight against MS. This webinar will give you…